Last reviewed · How we verify
Irbesartan monotherapy
Irbesartan blocks angiotensin II type 1 (AT1) receptors, preventing vasoconstriction and reducing blood pressure.
Irbesartan blocks angiotensin II type 1 (AT1) receptors, preventing vasoconstriction and reducing blood pressure. Used for Hypertension, Diabetic nephropathy in patients with type 2 diabetes and hypertension.
At a glance
| Generic name | Irbesartan monotherapy |
|---|---|
| Also known as | Avapro |
| Sponsor | Bristol-Myers Squibb |
| Drug class | Angiotensin II receptor blocker (ARB) |
| Target | AT1 receptor (Angiotensin II type 1 receptor) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Irbesartan is an angiotensin II receptor blocker (ARB) that selectively antagonizes AT1 receptors on vascular smooth muscle and other tissues. By blocking angiotensin II signaling, it causes vasodilation, reduces peripheral vascular resistance, and decreases aldosterone secretion, leading to lower blood pressure and reduced sodium retention. This mechanism also provides renal protection in patients with hypertension and diabetes.
Approved indications
- Hypertension
- Diabetic nephropathy in patients with type 2 diabetes and hypertension
Common side effects
- Dizziness
- Fatigue
- Musculoskeletal pain
- Hyperkalemia
- Cough
- Headache
Key clinical trials
- Antihypertensive Pharmacological Therapy With Mineralocorticoid Receptor Antagonists in Obese Hypertensive Patients (PHASE4)
- Impact of Antihypertensive Therapy on Recurrence Risk of Ovarian Cancer for Bevacizumab-associated Hypertension
- Study of Efficacy and Safety of Irbesartan/Amlodipine 4 Fixed Combination Therapy in Hypertensive Patients Uncontrolled on Irbesartan or Amlodipine Monotherapy (PHASE3)
- Irbesartan/Hydrochlorothiazide (HCTZ) Combination Therapy as First Line Treatment for Severe Hypertension (PHASE3)
- Irbesartan/Hydrochlorothiazide (HCTZ) Combination Therapy for Patients With Moderate Hypertension (PHASE3)
- Irbesartan and Amlodipine Combination in Controlling Blood Pressure (PHASE2)
- Irbesartan/Amlodipine in Hypertensive Patients Uncontrolled on Amlodipine 5 mg Monotherapy (PHASE3)
- Irbesartan/Amlodipine in Hypertensive Patients Uncontrolled on Irbesartan 150 mg Monotherapy (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Irbesartan monotherapy CI brief — competitive landscape report
- Irbesartan monotherapy updates RSS · CI watch RSS
- Bristol-Myers Squibb portfolio CI